gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
about
Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protectionPotentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protectionAntigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral LeishmaniasisLeishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasisIdentification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasisComparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular ApproachesMolecular cloning and expression analysis of peptidase genes in the fish-pathogenic scuticociliate Miamiensis avidus.Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.Development of Vaccines against Visceral LeishmaniasisImpact of Leishmania infection on host macrophage nuclear physiology and nucleopore complex integrity.A perspective on the emergence of sialic acids as potent determinants affecting leishmania biology.An overview on Leishmania vaccines: A narrative review article.In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasisNoninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India.Identification of BALB/c Immune Markers Correlated with a Partial Protection to Leishmania infantum after Vaccination with a Rationally Designed Multi-epitope Cysteine Protease A Peptide-Based Nanovaccine.Synthetic Peptides as Potential Antigens for Cutaneous Leishmaniosis Diagnosis.Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).Development of Leishmania vaccines: predicting the future from past and present experience.Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection.Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.DNA vaccines: a rational design against parasitic diseases.Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity.Cationic liposomes as vaccine adjuvants.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.Vaccine Development Against Leishmania donovani.Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.An overview of adjuvant formulations and delivery systems.Delivery systems for Leishmania vaccine development.DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.Proteoliposomes in nanobiotechnology.A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8(+) T CellsNanobiotechnologic approach to a promising vaccine prototype for immunisation against leishmaniasis: a fast and effective method to incorporate GPI-anchored proteins of Leishmania amazonensis into liposomes.A gp63 based vaccine candidate against Visceral LeishmaniasisComparison of liposome-polycation-DNA(LPD) and monophosphoryl lipid A(MPL) adjuvant formulations in BALB/c mice models.Liposomal adjuvant development for leishmaniasis vaccines.Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.The role of LPD-nanoparticles containing recombinant major surface glycoprotein of Leishmania (rgp63) in protection against leishmaniasis in murine model.Immunoprophylactic Potential of a Cocktail of Three Low Molecular Weight Antigens of Leishmania donovani along with Various Adjuvants Against Experimental Visceral leishmaniasis.
P2860
Q27304818-D1F760CE-FB1B-442C-98C6-1AC62B416F4EQ27305883-BDE79AE7-DEF5-474D-927D-CB3C390A8F8BQ27318412-5C7189B2-CBE6-432E-B928-19FC1DF85EADQ28483976-AA25D452-61EE-46BE-8660-8865C5D4465CQ33463435-C94C4536-CD3B-423D-BD17-30AF2BECE24AQ33615236-1B9B2174-2A32-4194-98CF-61EEA65511B6Q33818084-36C1C25A-F02F-4FCE-80A4-3B887FD74926Q34076804-56D983AC-06C7-4A8E-B068-0464627462EFQ34545937-8405B601-4BB1-43A6-902A-C19207FDE055Q34662190-8EAACD94-AF8E-4E32-B8FC-2781AF627C59Q35207606-38702E8B-CAE8-4E92-82FA-6885814853BAQ35235104-C61550F8-FF7C-4AC5-AB35-8B88FE356F3DQ35433080-9C6D84A3-F890-46B4-927F-D508B681C489Q35517074-802C3DDB-F240-43BF-9AF2-43FE68BDBD65Q35666654-E2D36C28-9285-4544-943E-CB87CBCFECC3Q36163680-71346121-E134-4B6A-9820-443333201886Q36257481-6BC662BA-8743-4361-8FFE-344C4FEC6E64Q36331367-7ABC91B0-38B1-48A3-BC9A-F51E45C25C54Q36680084-C009A49F-209C-4568-8894-D85B2DD73B42Q36700453-3452D40C-BF5D-441B-9103-DDA5A9D12A1DQ36708313-A3D0C027-418E-41E2-8A0F-EA494C957606Q36744853-41441F56-369D-44BF-B05B-94874D3273B8Q37682900-E30B5237-8292-4D65-8ED3-23E2069E4AB7Q37684378-3E0DB451-0F01-4947-BD5A-1C0C110D23BBQ37867105-672CA59D-AB26-49CA-9208-06BAE4141743Q37965724-0AB9202A-83F7-4B3C-8E1B-04F93EEDD37AQ38012112-2E3AAC4D-A476-4C4E-B14B-C9FC765CE129Q38028994-8676DDF0-2D7E-490F-9E8F-8327CF508C7FQ38126953-DD96DA49-A1A9-4906-A7B8-E8F9A7ED891CQ38746362-A76C9CF3-6C68-4726-ADDB-8A368DE9D327Q38786910-6958F0E4-21B1-4648-BAEB-FC0C4BD8329CQ39310225-782A2808-E161-4539-B481-159A12DCD1FFQ40649527-08811D68-59D5-40D2-976F-16C5C6044819Q41723457-C665FCDF-B02A-4255-B591-3B043E80890AQ42637823-1E84C009-DFB7-48E1-9CA6-B969F5A062FFQ45147728-656F70E1-1287-4610-8FDA-5D06B605196EQ47153161-28585BBB-2DE0-4934-88A3-3854868C7ED2Q49210114-55FE7795-5093-4264-80D4-DFFD4C06C524Q50054197-01CE7E33-B7E9-4D72-9E03-C3D11DA72067Q55405901-9979303E-3F57-45D8-844F-3B34B0A486B3
P2860
gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
gp63 in stable cationic liposo ...... cted with Leishmania donovani.
@en
gp63 in stable cationic liposo ...... cted with Leishmania donovani.
@nl
type
label
gp63 in stable cationic liposo ...... cted with Leishmania donovani.
@en
gp63 in stable cationic liposo ...... cted with Leishmania donovani.
@nl
prefLabel
gp63 in stable cationic liposo ...... cted with Leishmania donovani.
@en
gp63 in stable cationic liposo ...... cted with Leishmania donovani.
@nl
P2860
P356
P1476
gp63 in stable cationic liposo ...... ected with Leishmania donovani
@en
P2093
Swati Bhowmick
P2860
P304
P356
10.1128/IAI.00611-07
P407
P577
2008-01-14T00:00:00Z